PL2717692T3 - Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych - Google Patents

Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych

Info

Publication number
PL2717692T3
PL2717692T3 PL12796691T PL12796691T PL2717692T3 PL 2717692 T3 PL2717692 T3 PL 2717692T3 PL 12796691 T PL12796691 T PL 12796691T PL 12796691 T PL12796691 T PL 12796691T PL 2717692 T3 PL2717692 T3 PL 2717692T3
Authority
PL
Poland
Prior art keywords
fiberatal
tetrahydrocannabinol
owe
diseases
acids
Prior art date
Application number
PL12796691T
Other languages
English (en)
Inventor
Robert B. Zurier
Enrico Selvi
Original Assignee
Corbus Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals, Inc. filed Critical Corbus Pharmaceuticals, Inc.
Publication of PL2717692T3 publication Critical patent/PL2717692T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12796691T 2011-06-04 2012-06-01 Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych PL2717692T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161493435P 2011-06-04 2011-06-04
US13/485,044 US20120309820A1 (en) 2011-06-04 2012-05-31 Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP12796691.9A EP2717692B1 (en) 2011-06-04 2012-06-01 Tetrahydrocannabinol-11-oic acids for use in treating fibrotic diseases
PCT/US2012/040380 WO2012170290A1 (en) 2011-06-04 2012-06-01 Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids

Publications (1)

Publication Number Publication Date
PL2717692T3 true PL2717692T3 (pl) 2020-06-15

Family

ID=47262154

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12796691T PL2717692T3 (pl) 2011-06-04 2012-06-01 Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych

Country Status (8)

Country Link
US (3) US20120309820A1 (pl)
EP (2) EP2717692B1 (pl)
DK (1) DK2717692T3 (pl)
ES (1) ES2753639T3 (pl)
HU (1) HUE047419T2 (pl)
PL (1) PL2717692T3 (pl)
PT (1) PT2717692T (pl)
WO (1) WO2012170290A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160002709A (ko) * 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
JP6307290B2 (ja) * 2013-03-06 2018-04-04 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
EP3399974A4 (en) * 2016-01-08 2019-09-04 Colonaryconcepts LLC FOOD-BASED DELIVERY OF CANNABINOIDS
WO2017149387A1 (en) * 2016-03-04 2017-09-08 Sharon Anavi-Goffer Compositions of cb2 receptor selective agonists for treatment of mental disorders
AU2017258765A1 (en) * 2016-04-29 2018-11-29 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
US20210267959A1 (en) * 2018-07-17 2021-09-02 The Regents Of The University Of California Methods of treating renal disease
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022012578A (es) 2020-04-08 2022-11-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
KR20230016674A (ko) 2020-05-28 2023-02-02 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체
WO2021245186A1 (en) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
RS67140B1 (sr) 2020-06-08 2025-09-30 Mission Therapeutics Ltd 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds
GB202500610D0 (en) 2025-01-16 2025-03-05 Mission Therapeutics Ltd Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
WO2004058251A1 (en) * 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US8058227B2 (en) * 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8877188B2 (en) * 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis

Also Published As

Publication number Publication date
ES2753639T3 (es) 2020-04-13
WO2012170290A1 (en) 2012-12-13
EP2717692A4 (en) 2015-02-18
PT2717692T (pt) 2019-11-18
DK2717692T3 (da) 2019-11-11
HUE047419T2 (hu) 2020-04-28
EP2717692B1 (en) 2019-08-07
EP3620211A1 (en) 2020-03-11
US20120309820A1 (en) 2012-12-06
US20180116999A1 (en) 2018-05-03
EP2717692A1 (en) 2014-04-16
US20160367518A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
IL232256A0 (en) Novel purine derivatives and their use in the treatment of disease
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
IL228649B (en) Immunogenic compositions for use in therapy
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
PT2717692T (pt) Ácidos tetra-hidrocanabinol-11-oicos para utilização no tratamento de doenças fibróticas
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
GB2496688B (en) Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
HUE046239T2 (hu) Zsírsav keverékek gyulladásos megbetegedések kezelésében való alkalmazásra
EP2695154A4 (en) PROVIDING A COMPUTER-BASED LANGUAGE THERAPY
EP2718255A4 (en) QUINONE COMPOUNDS FOR THE TREATMENT OF APE1 MEDIATION DISEASES
GB2515439B (en) Vesicular formulations for use in the treatment of reduced mobility
IL234606B (en) Novel methods and composition for treatment of disease
IL229081A0 (en) Isoxazolines as therapeutic agents
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
CO6880064A2 (es) Métodos terapéuticos
PL3447070T3 (pl) Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
IL239078A0 (en) Protein for use in the treatment of eye diseases